Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02650674
Other study ID # KBE043
Secondary ID
Status Completed
Phase N/A
First received October 30, 2015
Last updated September 13, 2017
Start date October 2015
Est. completion date April 2016

Study information

Verified date September 2017
Source Mondelez International, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed at determining the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products in two different ethnic groups.


Description:

This study aimed at determining the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products in two different ethnic groups. It is a laboratory-based research study, conducted in two different ethnic groups, with an open cross-over design, including 24 healthy non-smoking voluntary subjects, aged from 18 to 45 years. 12 subjects will be Caucasian and 12 subjects will be Asian. 8 test sessions per subject are included in the study. Foods are consumed in a random order according to a randomisation list. The impact of the ethnic group and the products will be determined.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date April 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Aged between 18-45 years.

- Non-smoker.

- BMI values: between 19-25 kg/m2 (bounds included) for Caucasian subjects and between 19-23 kg/m2 (bounds included) for Asian subjects (WHO expert consultation).

- Ethnicity: Caucasian subjects will have both parents from Caucasian ancestry. Asian subjects will have both parents from Asian country and will be born in an Asian country. Asian countries are: Brunei Darussalam, Cambodia, China, Dem. People's Republic of Korea, Hong Kong SAR (China), Indonesia, Japan, Lao People's Democratic Republic, Macao SAR (China), Malaysia, Mongolia, Myanmar, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam.

- Sex ratio: Around half of the subjects should be male and half of the subjects should be female within each study group. A plus or minus 1 subject tolerance will be accepted.

- Healthy subjects with:

Normal glucose tolerance Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol); Normal systolic blood pressure (100-150 mmHg); Normal diastolic blood pressure (60-90 mmHg); Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).

- Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.

- Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week))

- Able to fast for at least 10 hours the night before each test session.

- Able to refrain from eating legumes and drinking alcohol the day before each test session.

- Subject covered by social security or covered by a similar system

- Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely to interfere with metabolism or dietary habits

- Subject having given written consent to take part in the study.

Exclusion Criteria:

- Following a restrictive diet.

- Family history of Diabetes Mellitus or obesity

- Suffering from any clinical, physical or mental illness.

- Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).

- Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication)

- Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.

- Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.

- Subject having taken part in another clinical trial within the last week.

- Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial.

- Subject undergoing general anaesthesia in the month prior to inclusion.

- Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Product A: NP-0148
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Glucose solution
Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
Product B: NP-0149
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Product C: NP-0150
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Product D: NP-0151
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Product E: NP-0152
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Locations

Country Name City State
Australia University of Sydney Sydney New South Wales

Sponsors (2)

Lead Sponsor Collaborator
Mondelez International, Inc. University of Sydney

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycaemic index values of five cereal products Determination of GI in both Caucasian and Asian subjects 2 hours after food consumption
Secondary Glycaemic response assessed by the glycemic index (GI) values of five cereal products Determination of GI in the global population 2 hours after food consumption
Secondary Glycaemic response assessed by the postprandial changes in glycaemia over 2 hours (iAUC0-120) after consumption of the test products This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Glycaemic response assessed by the kinetic of glycemia over the 120 minutes This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Glycaemic response assessed by the peak value of glycemia This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Glycaemic response assessed by the delta value between baseline and peak values of glycemia This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulinaemic response assessed by the insulinemic index (II) values of five cereal products This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulinaemic response assessed by the postprandial changes in insulinemia over 2 hours (iAUC0-120) after consumption of the test products This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulinaemic response assessed by the kinetic of insulinemia over the 120 minutes This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulinaemic response assessed by the peak value of insulinemia This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulinaemic response assessed by the delta value between baseline and peak values of insulinemia This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Insulin / glucose ratio (II/GI) evaluation of five cereal products This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Postprandial changes in insulin / glucose over 2 hours (iAUC0-120) after consumption of the test products This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Kinetic of insulin / glucose over the 120 minutes This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Peak value of insulin / glucose ratio This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
Secondary Delta peak value between baseline and peak values of insulin / glucose ratio This parameter will be analyzed first in both Caucasian and Asian populations and second globally 2 hours after food consumption
See also
  Status Clinical Trial Phase
Completed NCT00546052 - A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331) Phase 3
Completed NCT00707746 - Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Phase 2
Completed NCT02573103 - Air Pollution and Cardiovascular Disease
Not yet recruiting NCT06051461 - Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication N/A
Not yet recruiting NCT05013112 - Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) N/A
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Completed NCT01337141 - A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Recruiting NCT03882580 - Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Active, not recruiting NCT01911091 - Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus) N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Completed NCT03873948 - Evaluation of Arginine in Periodontal and Cardiovascular Disease
Completed NCT01738061 - A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan N/A
Completed NCT02059993 - The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease N/A
Completed NCT06129578 - Plant Protein Supplementation Within a Healthy Lifestyle Modulates Plasma Circulating Amino Acids and Improves the Health Status of Overweight Individuals N/A
Completed NCT06331572 - Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
Completed NCT05255718 - Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome N/A
Completed NCT00694109 - An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Phase 3